Sanctuary Advisors LLC Sells 19,801 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Sanctuary Advisors LLC cut its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 17.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 94,996 shares of the biopharmaceutical company’s stock after selling 19,801 shares during the period. Sanctuary Advisors LLC owned approximately 0.08% of Catalyst Pharmaceuticals worth $2,352,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in CPRX. Deerfield Management Company L.P. raised its holdings in shares of Catalyst Pharmaceuticals by 72.8% during the 3rd quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock worth $98,003,000 after acquiring an additional 2,095,291 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Catalyst Pharmaceuticals by 200.6% in the fourth quarter. Janus Henderson Group PLC now owns 1,719,767 shares of the biopharmaceutical company’s stock valued at $40,124,000 after purchasing an additional 1,147,565 shares in the last quarter. Morgan Stanley lifted its position in Catalyst Pharmaceuticals by 59.1% during the fourth quarter. Morgan Stanley now owns 2,933,399 shares of the biopharmaceutical company’s stock valued at $68,466,000 after purchasing an additional 1,089,775 shares during the last quarter. Glenmede Investment Management LP grew its stake in shares of Catalyst Pharmaceuticals by 781.8% in the 3rd quarter. Glenmede Investment Management LP now owns 680,224 shares of the biopharmaceutical company’s stock worth $13,400,000 after buying an additional 603,084 shares in the last quarter. Finally, Bank of America Corp DE raised its position in shares of Catalyst Pharmaceuticals by 30.6% during the 2nd quarter. Bank of America Corp DE now owns 2,365,675 shares of the biopharmaceutical company’s stock valued at $51,335,000 after buying an additional 554,200 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

NASDAQ:CPRX opened at $31.49 on Wednesday. The company has a market cap of $3.86 billion, a price-to-earnings ratio of 18.10, a price-to-earnings-growth ratio of 0.96 and a beta of 0.74. Catalyst Pharmaceuticals, Inc. has a twelve month low of $19.05 and a twelve month high of $32.56. The stock has a fifty day simple moving average of $31.37 and a 200-day simple moving average of $27.15.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. HC Wainwright downgraded Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $35.00 to $31.50 in a research report on Thursday, May 28th. Zacks Research lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th. Truist Financial upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, March 25th. Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Friday, March 27th. Finally, Wall Street Zen downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).